Literature DB >> 10094881

Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.

Z Zhang1, S D Barnhill, H Zhang, F Xu, Y Yu, I Jacobs, R P Woolas, A Berchuck, K R Madyastha, R C Bast.   

Abstract

A panel of four selected tumor markers, CA 125 II, CA 72-4, CA 15-3, and lipid-associated sialic acid, was analyzed collectively using an artificial neural network (ANN) approach to differentiate malignant from benign pelvic masses. A dataset of 429 patients, 192 of whom had malignant histology, was retrospectively used in the study. A prototype ANN classifier was developed using a subset of the data which included 73 patients with malignant conditions and 101 patients with benign conditions. The ANN classifier demonstrated a much improved specificity over that of the assay CA 125 II alone (87.5% vs 68.4%) while maintaining a statistically comparable sensitivity (79.0% vs 82.4%) in discriminating malignant from benign pelvic masses in an independent validation test using data from the remaining 255 patients which had been set aside and kept blind to the developers of the ANN system. A similar improvement in specificity was observed among patients under 50 years of age (82.3% vs 62.0%). The ANN system was further tested using additional serum specimens collected from 196 apparently healthy women. The ANN system had a specificity of 100.0% compared to that of 94.8% with the assay CA 125 II alone. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094881     DOI: 10.1006/gyno.1999.5320

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

2.  Combined use of biomarkers for detection of ovarian cancer in high-risk women.

Authors:  Martin Donach; Yinhua Yu; Grazia Artioli; Giuseppe Banna; Weiwei Feng; Robert C Bast; Zhen Zhang; Maria O Nicoletto
Journal:  Tumour Biol       Date:  2010-06

3.  The role of CA125 in clinical practice.

Authors:  E L Moss; J Hollingworth; T M Reynolds
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

4.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

5.  Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.

Authors:  Biaoyang Lin; James T White; Jian Wu; Shashikant Lele; Lloyd J Old; Leroy Hood; Kunle Odunsi
Journal:  Proteomics Clin Appl       Date:  2009-07-01       Impact factor: 3.494

6.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

Review 7.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

8.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Authors:  Zhen Zhang; Yinhua Yu; Fengji Xu; Andrew Berchuck; Carolien van Haaften-Day; Laura J Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Steven Skates; Daniel W Chan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2007-10-24       Impact factor: 5.482

9.  Neural network assessment of herbal protection against chemotherapeutic-induced reproductive toxicity.

Authors:  Amr Amin; Doaa Mahmoud-Ghoneim; Muhammed I Syam; Sayel Daoud
Journal:  Theor Biol Med Model       Date:  2012-01-24       Impact factor: 2.432

10.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.